BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22362554)

  • 1. Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.
    Oh SH; Whang YM; Min HY; Han SH; Kang JH; Song KH; Glisson BS; Kim YH; Lee HY
    Int J Cancer; 2012 Nov; 131(10):2253-63. PubMed ID: 22362554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
    J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
    Lee HY; Chun KH; Liu B; Wiehle SA; Cristiano RJ; Hong WK; Cohen P; Kurie JM
    Cancer Res; 2002 Jun; 62(12):3530-7. PubMed ID: 12068000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
    PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.
    Jin Q; Lee HJ; Min HY; Smith JK; Hwang SJ; Whang YM; Kim WY; Kim YH; Lee HY
    Carcinogenesis; 2014 Oct; 35(10):2232-43. PubMed ID: 24942865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
    Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
    Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Kim J; Guan J; Chang I; Chen X; Han D; Wang CY
    Mol Cancer Ther; 2010 Jul; 9(7):1977-84. PubMed ID: 20571067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events.
    Kim JH; Choi DS; Lee OH; Oh SH; Lippman SM; Lee HY
    Blood; 2011 Sep; 118(9):2622-31. PubMed ID: 21551235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
    Stauber RH; Knauer SK; Habtemichael N; Bier C; Unruhe B; Weisheit S; Spange S; Nonnenmacher F; Fetz V; Ginter T; Reichardt S; Liebmann C; Schneider G; Krämer OH
    Oncotarget; 2012 Jan; 3(1):31-43. PubMed ID: 22289787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
    Singh T; Prasad R; Katiyar SK
    Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
    Oh SH; Kim WY; Kim JH; Younes MN; El-Naggar AK; Myers JN; Kies M; Cohen P; Khuri F; Hong WK; Lee HY
    Clin Cancer Res; 2006 Jan; 12(2):653-61. PubMed ID: 16428512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
    Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
    Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
    Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.
    Oh SH; Kim WY; Lee OH; Kang JH; Woo JK; Kim JH; Glisson B; Lee HY
    Cancer Sci; 2012 Jul; 103(7):1259-66. PubMed ID: 22494072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.